Payment overview · 2025
General Payments
$294.75
13 reported records · 9 companies
Healthcare provider profile · identity verified
Seema Mohan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CAREFREE, AZ · NPI 1588604177
Verified facts
What the public records show
CMS Open Payments records show Seema Mohan, MD received $294.75 in general payments during 2025 across 13 reported records.
ABBVIE INC. accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $69.66 | 23.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $56.18 | 19.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.24 | 17.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.62 | 7.7% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $22.09 | 7.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.77 | 7.0% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $19.22 | 6.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.34 | 5.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.63 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $294.75 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $69.66 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $69.66 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $50.24 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $50.24 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $50.24 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.35 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 359 | 152 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 277 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 245 | 116 |
| Losartan Potassium | Losartan Potassium | 155 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 136 | 58 |
| Lisinopril | Lisinopril | 114 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 45 |
| Ibandronate Sodium | Ibandronate Sodium | 83 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 42 |
| Trazodone Hcl | Trazodone Hcl | 79 | 37 |
| Montelukast Sodium | Montelukast Sodium | 72 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 71 | 31 |
| Prednisone | Prednisone | 69 | 41 |
| Gabapentin | Gabapentin | 61 | 25 |
| Synthroid | Levothyroxine Sodium | 61 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 26 |
| Metformin Hcl | Metformin Hcl | 57 | 19 |
| Simvastatin | Simvastatin | 57 | 23 |
| Sertraline Hcl | Sertraline Hcl | 52 | 19 |
| Metformin Hcl Er | Metformin Hcl | 49 | 20 |
| Allopurinol | Allopurinol | 41 | 19 |
| Mirtazapine | Mirtazapine | 40 | 15 |
| Omeprazole | Omeprazole | 39 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 33 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 24 |
| Ezetimibe | Ezetimibe | 30 | 11 |
| Eliquis | Apixaban | 29 | 15 |
| Famotidine | Famotidine | 28 | 13 |
| Azithromycin | Azithromycin | 27 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 27 | 13 |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Estradiol | Estradiol | 24 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 24 | 13 |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Armour Thyroid | Thyroid,pork | 21 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Furosemide | Furosemide | 17 | 11 |
| Trulicity | Dulaglutide | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 13 |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $294.75 · 13 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, COMIRNATY, CREON, Cologuard Collection Kit, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, LINZESS, NEXLETOL, NP Thyroid 60, PREVNAR 20, PROLIA, The Cologuard Plus Collection Kit, Veozah | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error